Total Funding
57
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
107820
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Acquired by 
Spexis
Jeffrey D. Wager: Co-Founder, Chairman & CEOPast Role: Artisan Pharma, Co-founder, President & CEO
James Collins: Founder
About the Company
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial
infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide.
It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
